Navigation Links
DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference

VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The presentation will take place Monday, September 9th at 3:15 p.m. EDT in Room 7.02 at the Millennium Broadway Hotel in New York City.  The presentation will be webcast live at and available for 90 days.

Jeffrey Bacha, president and CEO of DelMar, will provide an overview of DelMar's timely progress in developing important, new chemotherapies for patients who have little to no therapeutic options. 

DelMar's lead drug, VAL-083, is being developed to treat glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 is approved in China to treat chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and in the United States.

Developing Essential New Treatments for Aggressive Brain Cancers

Fifty percent of patients with GBM will fail today's approved therapies, Temodar® and Avastin®.  Tumor resistance to Temodar is well documented and known to be caused by the MGMT enzyme. Studies by the National Cancer Institute and DelMar have shown that VAL-083 acts through a unique mechanism unaffected by MGMT and has activity against a range of cancers. 

DelMar is conducting a Phase I/II clinical trial to assess the safety and efficacy of VAL-083 as a potential new treatment for GBM patients who have failed standard therapies. In June, DelMar reported encouraging interim results from the trial at the American Society for Clinical Oncology (ASCO). Last month, the FDA allowed DelMar to accelerate the dose-escalation in the clinical trial.

Temodar generates more than US$950 million annually in global revenues, primarily from the treatment of brain cancer.

In addition to its clinical activities in the United States, DelMar has acquired the commercial rights to VAL-083 in China, where it is approved for chronic myelogenous leukemia (CML) and lung cancer. DelMar and its manufacturing partner, Guangxi Wuzhou Pharmaceuticals, plan to work with leading clinicians in China to develop new post-market data to support the sales and marketing of VAL-083 in these indications in China and to expand the market opportunities for the drug on a worldwide basis.

DelMar's Recent Highlights:

  • August: FDA Allows Accelerated Dose-escalation for VAL-083 Clinical Trial in Gliobastoma
  • July: VAL-083 Clinical Trial in Glioblastoma Expands to UC San Francisco (UCSF)
  • July: DelMar and Guangxi Wuzhou Announce Chinese Government Funding Award
  • July: First U.S. Patent Issued for VAL-083, Part of International IP Strategy

Follow us on Twitter @DelMarPharma and use #Rodman2013 for conference updates.  

About DelMar Pharmaceuticals

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme, the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations,

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at
2. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
3. DelMar Pharmaceuticals, Inc. to Webcast, Live, at June 6th
4. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
5. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
6. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
7. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
8. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
9. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
10. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
11. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
Post Your Comments:
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the Global Cell Surface Testing Market: ... report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... , ... November 25, 2015 , ... For the first ... “ Two Organizations, One Beat ” campaign. The partnership between the two groups began ... aid in MAP International’s cause. , MAP International was founded in 1954 and is ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based ... celebrate their sobriety and show through pictures what a positive difference it makes. ... Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer ... 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that on ...
Breaking Medicine News(10 mins):